BEYOND AIR INC (XAIR)

Company Profile

Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in developing a platform for nitric oxide generators and delivery systems. The company is headquartered in Garden City, New York and currently employs 98 full-time employees. The company went IPO on 2019-05-07. The Company’s LungFit platform can be used to treat patients on ventilators that require NO, as well as patients with chronic or acute severe lung infections through delivery through a breathing mask or similar apparatus. The Company’s areas of focus with LungFit are persistent pulmonary hypertension of the newborn (PPHN), viral community-acquired pneumonia (VCAP), including COVID-19, bronchiolitis (BRO), nontuberculous mycobacteria (NTM) lung infection and various severe lung infections with underlying chronic obstructive pulmonary disease (COPD). Its LungFit PH is an ionizer technology that generates on-demand NO from ambient air and, regardless of dose or flow, delivers it to a ventilator circuit. The LungFit can generate up to 400 parts per million (ppm) of NO.

Company Info

BEYOND AIR INC

900 Stewart Avenue, Suite 301

Garden City NEW YORK 11530

P: 15166658200

CEO: Steven Lisi

Employees: 98

Website: https://www.beyondair.net/